Robots on the Rise: Record Orders and Rapid Growth for Dongguan Enterprises in 2026

Robots are working tirelessly! On the sixth day of the Lunar New Year, they have returned to work to fulfill orders!

In the water town of Hongmei, businesses are experiencing a strong start to the new year, with a surge in orders.

At Dongguan Hanyi Industrial Co., Ltd. (hereinafter referred to as “Hanyi Industrial”), the production workshop reflects a busy and orderly scene of intelligent manufacturing: robotic arms efficiently handle transportation, processing, and assembly, while AGV intelligent robots navigate the workshop, autonomously transferring materials. As a part of Hanyi Industrial’s integrated digital factory, the automation rate of the molding process here has exceeded 90%.

“The start of this year is promising, with a significant number of orders. We resumed operations on the sixth day of the Lunar New Year, and we expect our performance to grow by 40% to 50% this year,” said XU Jianxi, Chairman of Hanyi Industrial. Thanks to the company’s ongoing digital transformation and intelligent manufacturing initiatives, current orders are scheduled until July 2026, indicating robust growth potential.

In terms of market expansion, Hanyi Industrial reported early success at the start of 2026. Before and after the Spring Festival, the company participated in an exhibition in the United States, seizing opportunities in the overseas market and successfully securing a large number of new orders during the event and holiday period, laying a solid foundation for growth throughout the year.

Hanyi Industrial boasts a class 10,000 clean injection molding workshop and a precision injection workshop. Its core product lines encompass nine high-tech fields, including medical components, automotive parts, electronic products, smart products, security products, energy-saving products, home appliances, robotic components, and industrial products. This year’s growth is primarily driven by new orders in humanoid robots, new energy vehicles, and the medical sector, with digital products standing out as a significant catalyst for performance improvement.

As an intelligent factory focused on mold development, injection molding, and product assembly, Hanyi Industrial is dedicated to providing global clients with one-stop OEM/ODM services. The company currently serves clients across developed regions including North America, Europe, the UK, Japan, Canada, and Mexico. Despite challenges posed by export tariffs, the high quality, efficiency, and cost-effectiveness of products stemming from the intelligent production system have allowed Hanyi Industrial to maintain strong competitiveness in overseas markets, continuously winning the favor of international clients.

Dongguan Asia Pharmaceutical Technology Co., Ltd. has seen order growth surpassing 30%, with production schedules extending to June. In the finished goods warehouse of Asia Pharmaceutical, staff are busy counting items, with neatly stacked boxes of “Cold Remedy Granules” ready for shipment to various locations across the country. “We are operating at full capacity right from the start, with a staff return rate of 98%. Orders have increased by over 30% year-on-year, and production is scheduled through June,” said Tian Fusheng, General Manager and Party Branch Secretary of Asia Pharmaceutical. This positive trend is attributed to the optimization of the product matrix and deep market expansion.

The growth in orders is a result of the company’s in-depth exploration of existing product resources and market opportunities. According to Tian, Asia Pharmaceutical holds 97 drug approvals, with previous focus on around 20 products such as Urinary Stone Relief Pills and Shuanghuanglian Oral Solution. This year, the company formed a dedicated sales team to operate more precisely, successfully revitalizing traditional products like Xinli Pills and Xinyin Bi Yan Pills, achieving comprehensive coverage of all approvals and product categories. At the same time, the sales team has expanded significantly, extending the sales network from its original regions to most provinces nationwide, and continuously strengthening partnerships with chain pharmacies, hospitals, and clinics to enhance its omni-channel marketing system, providing strong support for steady sales growth.

As a national high-tech enterprise, Asia Pharmaceutical prioritizes research and development, maintaining a research investment ratio of over 5% of sales. This focus supports new drug development, secondary development of existing products, and the layout of classic formulations. The company has cultivated star products like the Urinary Stone Relief Pills, Cold Remedy Granules, and Shuanghuanglian Oral Solution, establishing strong brand recognition in the market. Founded in 1989, Asia Pharmaceutical is a modern pharmaceutical enterprise integrating research, production, and sales, primarily manufacturing nearly a hundred varieties across six dosage forms, including solutions, syrups, pills, tablets, and hard capsules.